Patents Represented by Attorney Duke M. Fitch
  • Patent number: 8048907
    Abstract: The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: November 1, 2011
    Assignee: Glaxo Group Limited
    Inventors: Laura J Chambers, Robert Gleave, Stefan Senger, Daryl Simon Walter
  • Patent number: 7935832
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R2 represents hydrogen, halogen, C1-6 alkyl, C6-10 arylmethyl-, C2-6 alkenyl, C2-6 alkynyl or C3-6 cycloalkylmethyl-; and any of said C1-6 alkyl, C6-10 arylmethyl-, C2-6 alkenyl, C2-6 alkynyl or C3-6 cycloalkylmethyl- is optionally substituted with 1, 2 or 3 halogen atoms; and R3 represents hydrogen, fluorine or methyl; or R2 and R3 together with the carbon atoms to which they are attached form a benzene ring optionally substituted with 1, 2 or 3 substituents, which may be the same or different, selected from the group consisting of C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl. The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: May 3, 2011
    Assignee: Glaxo Group Limited
    Inventors: Robert James Gleave, David George Hubert Livermore, Daryl Simon Walter
  • Patent number: 7932282
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: The compounds or salts modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor (P2X7 receptor antagonists). The invention also provides the use of such compounds or salts, or pharmaceutical compositions thereof, in the treatment or prevention of disorders/diseases mediated by the P2X7 receptor, for example pain, inflammation or a neurodegenerative disease, in particular pain such as inflammatory pain, neuropathic pain or visceral pain.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: April 26, 2011
    Assignee: Glaxo Group Limited
    Inventors: Paul John Beswick, David Kenneth Dean, Robert James Gleave, Andrew Peter Moses, Daryl Simon Walter
  • Patent number: 7928108
    Abstract: The invention provides 3-(methyloxy)-1-{4-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]butyl}-2(1H)-pyridinone of formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: April 19, 2011
    Assignee: Glaxo Group Limited
    Inventors: Gabriella Gentile, Valeria Zucchelli
  • Patent number: 7902394
    Abstract: Novel calcilytic compounds of Formula (I), pharmaceutical compositions, methods of synthesis, and methods of using them are provided.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: March 8, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Robert W. Marquis, Jr., Joshi M. Ramanjulu, Robert Trout
  • Patent number: 7888347
    Abstract: The present invention relates to novel pyrazole derivatives of formula I having pharmacological activity as H3 antagonists processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Grant
    Filed: July 4, 2006
    Date of Patent: February 15, 2011
    Assignee: Glaxo Group Limited
    Inventors: Mark James Bamford, David Matthew Wilson
  • Patent number: 7799773
    Abstract: The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: September 21, 2010
    Assignee: Glaxo Group Limited
    Inventors: Mark James Bamford, David Kenneth Dean, Sanjeet Singh Sehmi, David Matthew Wilson, Jason Witherington
  • Patent number: 7732600
    Abstract: Disclosed are methods for the preparation of compounds of formula (I): wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: June 8, 2010
    Assignee: Glaxo Group Limited
    Inventors: Markus Bergauer, Barbara Bertani, Matteo Biagetti, Steven Mark Bromidge, Alessandro Falchi, Colin Philip Leslie, Giancarlo Merlo, Domenica Antonia Pizzi, Marilisa Rinaldi, Luigi Piero Stasi, Jessica Tibasco, Antonio Kuok Keong Vong, Simon Edward Ward
  • Patent number: 7718693
    Abstract: The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: May 18, 2010
    Assignee: Glaxo Group Limited
    Inventor: Daryl Simon Walter
  • Patent number: 7704994
    Abstract: The present invention relates to benzazepine derivatives of formula (I) wherein: R1 represents —C3-7 cycloalkyl optionally substituted by C1-3 alkyl; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: April 27, 2010
    Assignee: Glaxo Group Limited
    Inventors: Sanjeet Singh Sehmi, David Matthew Wilson, Jason Witherington
  • Patent number: 7696193
    Abstract: The present invention relates to benzazepine derivatives of formula (I) wherein: R1 represents —C3-7 cycloalkyl optionally substituted by C1-3 alkyl; having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: April 13, 2010
    Assignee: Glaxo Group Limited
    Inventors: Sanjeet Singh Sehmi, David Matthew Wilson, Jason Witherington
  • Patent number: 7592346
    Abstract: Disclosed are methods for use of compounds of formula (I) in combination with other active substances in the treatment of CNS disorders such as depression or anxiety. wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: September 22, 2009
    Assignee: Glaxo Group Limited
    Inventors: Markus Bergauer, Barbara Bertani, Matteo Biagetti, Steven Mark Bromidge, Alessandro Falchi, Colin Philip Leslie, Giancarlo Merlo, Domenica Antonia Pizzi, Marilisa Rinaldi, Luigi Piero Stasi, Jessica Tibasco, Antonio Kuok Keong Vong, Simon Edward Ward
  • Patent number: 7459456
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: December 2, 2008
    Assignee: Glaxo Group Limited
    Inventors: Matteo Biagetti, Alessandro Falchi, Colin Philip Leslie, Giancarlo Merlo, Domenica Antonia Pizzi, Marilisa Rinaldi, Luigi Piero Stasi, Jessica Tibasco
  • Patent number: 7439245
    Abstract: Disclosed is a method for use of phenyl sulfone compounds of formula (I) in the treatment of anxiety.
    Type: Grant
    Filed: May 13, 2008
    Date of Patent: October 21, 2008
    Assignee: Glaxo Group Limited
    Inventors: Gregor James MacDonald, Mervyn Thompson